antiPLA2R Positive clinical trials at UCSF
1 research study open to eligible people
Showing trials for
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
open to eligible people ages 18-80
This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
San Francisco, California and other locations
Last updated: